The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned, along with the other GMP sites in Montreal, Limerick and Ahmedabad
Actylis has announced the opening of a new 30,000 sqft cGMP facility in Eugene, Oregon.
Gilles Cottier, Chief Executive Officer of Actylis, said: “Today we are delighted to announce that this purpose-built 30,000 sqft facility has commenced operations, allowing us to develop and manufacture GMP APIs and Pharma intermediates from clinical trial to commercial volumes.”
Cottier added: “We designed this facility specifically to enable us to develop and produce innovative APIs for our customers. Our intimate knowledge of their needs, our consultative approach, and focus on innovation offer unparalleled choice and flexibility. We worked closely with architect firm BCA (Blaise Cacciola Architect) and Coffman Engineering to build a facility that has the most up-to-date technology and equipment available.”
Commissioning and qualifications for clinical GMP were completed at the end of January this year and we already have our first projects completed and more are underway.
Christine Bellmor, Site Director, elaborated on some of the specific capabilities of the site: “We are excited to have this state-of-the-art facility here in Eugene come on line after such an intensive design and development process. We have seven manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3. We have a number of different reactors to allow flexibility for a variety of chemistries. Commissioning and qualifications for clinical GMP were completed at the end of January this year and we already have our first projects completed and more are underway. The new facility is a 10 minute drive from our R&D facility which is critical for scaling and developing new processes for the plant. We are very proud of the site and look forward to welcoming customers to the facility so that they can see for themselves the capabilities we offer.”
The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned – along with the other GMP sites in Montreal (Canada), Limerick (Ireland) and Ahmedabad (India), Actylis boasts a presence in 10 countries spanning three continents and offers more than 4,500 products. Actylis offers customers the flexibility to choose from a wide range of individualised solutions, all backed by the same world-class quality, supply chain reliability and regulatory expertise. Its capabilities encompass the entire R&D, product development and manufacturing spectrum, including technical sales support, R&D, manufacturing and production, quality, supply chain, global sourcing, and regulatory compliance.